EP689 Cytoreduction and hyperthermic intraperitoneal chemotherapy followed by hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) in advanced peritoneal carcinomatous (APC) at the american university of beirut medical center (AUBMC) experience 2007–2018: a retrospective review

Introduction/Background Peritoneal carcinomatosis (PC) has been traditionally considered a terminal disease with median survivals reported in literature of 6–12 months. Cytoreductive surgery (CRS) & hyperthermic intra-peritoneal chemo-therapy (HIPEC) have gradually gained acceptance as standard of care to manage selected PC cases. Our objective is to review the outcome of patients with APC who underwent CRS+HIPEC by the HIPEC team at the AUBMC Methodology All patients with APC were evaluated by the HIPEC team for eligibility and the majority had either gastrointestinal or gynecological malignancies. We retrospective reviewed data related to their demographics/tumor origin/surgical completeness/adverse events/outcome Results Since 2007, 53 patients (45% were females) were had CRS and HIPEC. 20 (37.6%) had Pseudomyxoma peritonei (PMP), 12 (23%) ovarian cancer, 14 (26.4%) colorectal cancer, 4 (7.5%) had gastric cancer, 2 (3.7%) had Mesothelioma and one (1.8%) Desmoplastic round cell tumor. Operative and Postoperative demographics and survivals are shown in tables 1 and 2. Median progression free (PFS) and overall survival (OS) are expressed in months. Conclusion We report the successful establishment of an active peritoneal surface malignancy multidisciplinary treatment program with results comparable to other centers. Careful patient selection, a multidisciplinary approach and proper surgical training and technique are essential for the success of such a program. Disclosure Nothing to disclose.